|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-8-1
|
|
pubmed:abstractText |
This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur-uracil (UFT) with leucovorin (LV) combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC). Patients received oral UFT 250 mg m(-2) day(-1) and LV 90 mg day(-1) in three divided daily doses for 14 days followed by a 1-week rest and i.v. irinotecan 250 mg m(-2) as a 90-min infusion every 3 weeks. Tumour responses, assessed every two cycles using RECIST criteria, were reviewed by an independent review committee. In 52 evaluable patients, the best overall response rate was 33% (95% confidence intervals (CI) 20-47%; 1 complete and 16 partial responses). The median time to progression was 5.4 months (95% CI 3.02-7.52 months) and median overall survival was 14.9 months (11.73-17.97 months). A total of 307 cycles were administered, with a median number of five cycles per patient (range: 1-10). The most common grade 3/4 toxicities were neutropenia (25% of patients), diarrhoea (22%), vomiting (11%) and anaemia (11%). The TEGAFIRI regimen is a feasible, well-tolerated and convenient treatment option for patients with non-resectable mCRC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-10744089,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-11006366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-11161231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-12202661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-12202662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-12881390,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-14735168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-15689586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-15868381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-17213824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-6814451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-8459266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-8562173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-9440757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-9653495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-9807986,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17637682-9807987
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:ArtruPP,
pubmed-author:BennounaJJ,
pubmed-author:BugatRR,
pubmed-author:DelordJ-PJP,
pubmed-author:DesseigneFF,
pubmed-author:DouillardJ YJY,
pubmed-author:FarouxRR,
pubmed-author:FrançoisEE,
pubmed-author:HusseiniFF,
pubmed-author:NamanHH,
pubmed-author:PerrierHH,
pubmed-author:PiedboisPP,
pubmed-author:SmithDD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-301
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17637682-Adult,
pubmed-meshheading:17637682-Aged,
pubmed-meshheading:17637682-Aged, 80 and over,
pubmed-meshheading:17637682-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17637682-Camptothecin,
pubmed-meshheading:17637682-Colorectal Neoplasms,
pubmed-meshheading:17637682-Female,
pubmed-meshheading:17637682-Humans,
pubmed-meshheading:17637682-Leucovorin,
pubmed-meshheading:17637682-Male,
pubmed-meshheading:17637682-Middle Aged,
pubmed-meshheading:17637682-Neoplasm Metastasis,
pubmed-meshheading:17637682-Tegafur,
pubmed-meshheading:17637682-Treatment Outcome,
pubmed-meshheading:17637682-Uracil
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
|
|
pubmed:affiliation |
Institut Claudius Regaud, 20-24 rue du Pont saint Pierre, Toulouse 31052, France. delord.jean-pierre@claudiusregaud.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
